Janssen Research & Development announced today that the FDA has granted Priority Review for...
Janssen Pharmaceuticals has announced that the FDA approved the supplemental New Drug...
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.
The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."
Janssen Research & Development, LLC has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIOT in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease. Janssen-Cilag International will market the drug under the name Vokanamet.
Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.
The Scripps Research Institute Announces New Research and License Agreement with Janssen PharmaceuticalsMay 7, 2013 7:58 am | News | Comments
The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus.
Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the FDA seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients.
Janssen R & D Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator DatabankNovember 15, 2012 3:03 am | News | Comments
Janssen Research & Development, LLC today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort.
FDA Grants Priority Review for XARELTO Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PEJuly 9, 2012 4:42 am | News | Comments
Janssen Research & Development, LLC announced today the U.S. FDA has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO.
Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region.
Forest Laboratories, Inc. today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, and Janssen Pharmaceutica NV entered into an agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic.
FORMA Therapeutics has announced an exclusive alliance with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.
Shire plc announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States in an agreement with Janssen Pharmaceutica N.V.
NUCYNTA ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic PainAugust 26, 2011 5:01 am | News | Comments
Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA ER, an oral analgesic taken twice daily, for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer.
Valeant Pharmaceuticals has signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. Valeant will pay Janssen $345 million for the assets, which includes prescription brands RETIN-A MICRO, ERTACZO, and RENOVA.
Galapagos NV announced today that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full rights to discover, develop and commercialize novel medicines on these targets.
INDIANAPOLIS (AP) — Eli Lilly and Co. said today it plans to buy the animal health business of Janssen Pharmaceutical NV in a deal that would give Lilly's Elanco division about 50 marketed animal health products.
Galapagos' Affiliate Argenta And Janssen Pharmaceutica Enter Into Integrated Cancer Drug Discovery Service AgreementOctober 4, 2010 5:15 am | News | Comments
Galapagos NV announced today that its affiliate, Argenta Discovery 2009 Limited, has entered into a drug discovery service agreement with Janssen Pharmaceutica N.V., aimed at delivering novel cancer drug candidates.
Basilea Pharmaceutica Ltd. has announced that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland.
Out of the Shadow, Susan Smiley's award-winning documentary film, is now available to view on our European Psychiatry 24x7 website www.psychiatry24X7.com.
Every month, GPSG Brazil’s manufacturing plant in São José dos Campos, processes more than 10,000 analyses to ensure the quality of nearly 2000 samples of raw materials, packaging materials, semi-finished and finished products, in addition to water and stability testing. The site is fully equipped with an incoming laboratory plus microbiological, chemical, analytical development and research and development laboratories.
WuXi PharmaTech Inc., a pharmaceutical , biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. , to collaborate in the area of preclinical services.
Basilea Pharmaceutica Ltd. has announced that after the negative decision by the CHMP today, Cilag GmbH International, a Johnson & Johnson company, has given notice that it will return global rights of ceftobiprole to Basilea.
Priligy™ (dapoxetine) receives first regulatory approvals for the treatment of premature ejaculation (PE) in Finland and Sweden
- Page 1